|Videos|June 4, 2021

Pipeline: Presbyopia treatment to finish Phase 3 late 2021

Orasis Pharmaceuticals drop in development for treating presbyopia

Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.


Latest CME